Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study

European Urology
Dimitrios PectasidesSotirios A Raptis

Abstract

To investigate the efficacy and tolerability of the combination of oxaliplatin and irinotecan in patients with relapsed or cisplatin-refractory germ cell tumors (GCT). Eighteen patients with relapsed or cisplatin-refractory GCT were treated with oxaliplatin 85 mg/m(2) on days 1 and 15, followed by irinotecan 80 mg/m(2) on days 1, 8 and 15, every four weeks for a maximum of six cycles. All patients were assessable for response and toxicity. Overall, 7 patients (40%) achieved a favorable response (4 complete and 3 partial responses). One of the complete responders relapsed after 2.5 months and despite further treatment with high dose chemotherapy, he died two months later. The remaining 3 patients are continuously disease free for 11+, 14+ and 19+ months. The partial responders subsequently progressed and died after 2, 3 and 4.5 months, respectively. None of the patients with extragonadal mediastinal GCT responded to oxaliplatin and irinotecan chemotherapy. The investigated combination has a good tolerance. Neutropenia related toxicity (grade 3/4, 17%), neutropenic infections and sepsis were not common probably due to prophylactic use of hematopoietic colony stimulating factor (G-CSF). Thrombocytopenia and anemia were not a serio...Continue Reading

References

Feb 20, 1992·International Journal of Cancer. Journal International Du Cancer·Y KanoY Miura
Jun 1, 1982·Cancer Treatment Reviews·S D Williams, L H Einhorn
Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·C BokemeyerR Souchon
Nov 1, 1994·International Journal of Cancer. Journal International Du Cancer·L XuR S Chaganti
Jan 1, 1994·Cancer Treatment Reviews·G J CreemersJ Verweij
Jan 1, 1995·Investigational New Drugs·H S PucR J Motzer
Jan 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerH J Schmoll
Jul 24, 1997·The New England Journal of Medicine·G J Bosl, R J Motzer
Aug 26, 1998·International Journal of Urology : Official Journal of the Japanese Urological Association·T MikiA Okuyama
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Werner ScheithauerDieter Depisch
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stuart HintonGeorge Wilding
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C KollmannsbergerC Bokemeyer
Aug 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N KemenyM A Graham
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C KollmannsbergerC Bokemeyer
Jan 24, 2004·Investigational New Drugs·G Varuni KondaguntaRobert J Motzer
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PectasidesD Skarlos
Dec 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Nov 17, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerUNKNOWN German Testicular Cancer Study Group

❮ Previous
Next ❯

Citations

Nov 12, 2005·Cancer Chemotherapy and Pharmacology·Britta K StordalRoss A Davey
Apr 4, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C TheodoreA Flechon
Apr 9, 2005·Current Opinion in Oncology·Arif Hussain
Oct 6, 2007·Postgraduate Medical Journal·Omar Khan, Andrew Protheroe
Dec 3, 2015·Expert Opinion on Pharmacotherapy·Christoph OingCarsten Bokemeyer
Mar 7, 2006·Lancet·Alan HorwichRobert Huddart
Mar 9, 2018·Expert Review of Anticancer Therapy·Christoph OingCarsten Bokemeyer
Feb 8, 2006·Cancer·Christian KollmannsbergerCarsten Bokemeyer
Mar 11, 2005·Expert Review of Anticancer Therapy·Robert A Huddart, Alison J Birtle
Oct 21, 2009·BJU International·Gedske Daugaard
Apr 10, 2010·International Journal of Urology : Official Journal of the Japanese Urological Association·Terukazu Nakamura, Tsuneharu Miki
Mar 9, 2019·Expert Opinion on Pharmacotherapy·Winfried AlsdorfChristoph Oing
Dec 22, 2006·Bulletin of Experimental Biology and Medicine·T G BorovskayaA V Pakhomova
May 13, 2008·Expert Review of Anticancer Therapy·Syed A HussainMichael H Cullen
Jan 18, 2007·The Oncologist·Guru SonpavdeBruce J Roth
Jun 29, 2011·Bulletin du cancer·Caroline EvenThibault de La Motte Rouge
Nov 17, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerUNKNOWN German Testicular Cancer Study Group
Aug 1, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A NecchiR Salvioni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
D PectasidesD Skarlos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C KollmannsbergerC Bokemeyer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Stuart HintonGeorge Wilding
© 2022 Meta ULC. All rights reserved